Influenza A virus vaccine H5N1 - PaxVax

Drug Profile

Influenza A virus vaccine H5N1 - PaxVax

Alternative Names: Ad4-H5-Vtn; PXVX-0103

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PaxVax
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention, In volunteers) in USA (PO, Capsule)
  • 31 Jan 2013 Immunogenicity data from a phase I trial in healthy volunteers released by PaxVax
  • 31 Dec 2011 PaxVax completes a Phase-I trial in Influenza-A virus H5N1 subtype (in volunteers, prevention) in USA (NCT01006798)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top